Global Androgen Receptor Inhibitor Market - 2024-2031

Global Androgen Receptor Inhibitor Market - 2024-2031

Global Androgen Receptor Inhibitor market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

An androgen receptor inhibitor used to treat metastatic carcinoma of the prostate. Androgen receptor inhibitor is also known as androgen antagonists or testosterone blockers. These are a class of drugs that prevent androgens like testosterone and dihydrotestosterone (DHT) from mediating their biological effects in the body. They act by blocking the androgen receptor (AR) and/or inhibiting or suppressing androgen production.

Androgen receptor inhibitors are used in the treatment of an assortment of androgen-dependent conditions in both males and females. They are used to treat men with prostate cancer, benign prostatic hyperplasia, and others and in women and girls, antiandrogens are used to treat acne, seborrhea, and hyperandrogenism among others

Market Dynamics: Drivers & Restraints

The increasing burden of cancer

The rising burden of prostate cancer in individuals with androgenic alopecia, benign prostatic hyperplasia along other conditions is expected to drive the market growth.

For instance, according to the American Society of Cancer in 2024, it is estimated that 1 in 8 men are diagnosed with prostate cancer during their lifetime. The risk of prostate cancer varies among individuals based on their age, race and other factors.

Prostate cancer is estimated to develop in older men. About 6 in 10 prostate cancers are diagnosed in men who are 65 or older, and it is rare in men under 40. The average age of men when they are first diagnosed is about 67. It is estimated that about 299,010 new prostate cancer cases are expected to be diagnosed with prostate cancer. Thus, the above factors are expected to drive the market growth

Side effects associated with the inhibitors

Apart from the favorable outcomes, androgen receptor inhibitors have numerous side effects which are used in androgen-deprivation therapy. Side effects such as fatigue, anemia, bone mineral density loss and increase in the risk of breaking the bone, an increase in body mass, insulin resistance, and hypercholesterolemia. Thus, the above factors are expected to hinder the market growth.

Segment Analysisn

The global medical drones market is segmented based on type, indication, distribution channel and region.

The androgen synthesis inhibitors segment is expected to dominate the market growth

Androgen synthesis inhibitors (ASIs) are a class of drugs that reduce the body's production of androgens, primarily testosterone. Treatments for ailments including acne, prostate cancer, and excessive hair growth may benefit from this.

CRPC, in which the cancer cells proliferate even after castration or other therapies that reduce testosterone levels, is a common outcome for people with prostate cancer. In contrast to these conventional techniques, ASIs function by preventing the synthesis of androgens at distinct points along the synthesis route. For individuals with CRPC, this may offer further advantages in terms of tumor development management. Thus, the above factors are expected to hold the segment in the dominant position over the forecast period.

Geographical Analysis

North America is expected to hold a significant position in the androgen receptor inhibitor market share

North America holds a dominant position in the market share due to the high prevalence of prostate cancers and also the increased use of different kind of therapies that uses androgen receptor inhibitors. The increased research and developmental activities will also act as a factor for the growth of the market in the region.

The increase in research and developmental activities and the introduction of new drug options are also expected to drive the region's market growth. For instance, in November 2023, Astellas Pharma Inc. and Pfizer Inc. received companies received approval by the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for XTANDI (enzalutamide). Thus, increase in the number of launches of new drugs in the region is expected to hold the region in the dominant position.

COVID-19 Impact Analysis

COVID-19 has had a significant impact on the androgen receptor inhibitors market growth. The shift of the research and developmental activities towards introducing new medication for COVID-19 has reduced the production of the androgen receptor inhibitors. The supply chains have been interrupted due to the lockdown and also the stringent regulations by the government across the borders of the region. Thus, COVID-19 has a negative impact on the market growth.

Market Segmentation

By Type
• Androgen Synthesis Inhibitor
CYP17A1 Inhibitors

 17α-hydroxylase

 17,20-lyase Inhibitors

 Abiraterone

 Others
• Androgen Receptor Antagonists
Enzalutamide
Flutamide
Spironolactone
Others

By Indication
• Prostate Cancer
• Benign Prostatic Hyperplasia
• Others

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Pfizer Inc., Astellas Pharma Inc., Sanofi SA, Johnson & Johnson Inc., Dr.Reddy's Laboratories, Novartis AG, MANUS AKTTEVA BIOPHARMA LLP, RPG Life Sciences Limited, Kekule Pharma and LEXICARE PHARMA PVT. LTD. among others.

Why Purchase the Report?
• To visualize the global androgen receptor inhibitor market segmentation based on type, indication, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of androgen receptor inhibitor market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global androgen receptor inhibitor market report would provide approximately 53 tables, 49 figures and 182 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies